M
Michael J. Reardon
Researcher at Houston Methodist Hospital
Publications - 526
Citations - 18525
Michael J. Reardon is an academic researcher from Houston Methodist Hospital. The author has contributed to research in topics: Valve replacement & Aortic valve replacement. The author has an hindex of 49, co-authored 443 publications receiving 14508 citations. Previous affiliations of Michael J. Reardon include The Texas Heart Institute & Cornell University.
Papers
More filters
Journal ArticleDOI
Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis
David H. Adams,Jeffrey J. Popma,Michael J. Reardon,Steven J. Yakubov,Joseph S. Coselli,G. Michael Deeb,Thomas G. Gleason,Maurice Buchbinder,James B. Hermiller,Neal S. Kleiman,Stan Chetcuti,John Heiser,William Merhi,George L. Zorn,Peter Tadros,Newell Robinson,George Petrossian,G. Chad Hughes,J. Kevin Harrison,John V. Conte,Brijeshwar Maini,Mubashir Mumtaz,Sharla Chenoweth,Jae K. Oh +23 more
TL;DR: In patients with severe aortic stenosis who are at increased surgical risk, TAVR with a self-expanding transcatheter aorti-valve bioprosthesis was associated with a significantly higher rate of survival at 1 year than surgical aorticsvalve replacement.
Journal ArticleDOI
Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients
Jeffrey J. Popma,G. Michael Deeb,Steven J. Yakubov,Mubashir Mumtaz,Hemal Gada,Daniel O'Hair,Tanvir Bajwa,John Heiser,William Merhi,Neal S. Kleiman,Judah Askew,Paul Sorajja,Joshua Rovin,Stanley Chetcuti,David H. Adams,P.S. Teirstein,George L. Zorn,John K. Forrest,Didier Tchetche,Jon R. Resar,Antony Walton,Nicolo Piazza,Basel Ramlawi,Newell Robinson,George Petrossian,Thomas G. Gleason,Jae K. Oh,Michael J. Boulware,Hongyan Qiao,Andrew S. Mugglin,Michael J. Reardon +30 more
TL;DR: In patients with severe aortic stenosis who were at low surgical risk, TAVR with a self‐expanding supraannular bioprosthesis was noninferior to surgery with respect to the composite end point of death or disabling stroke at 24 months.
Journal ArticleDOI
Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients
Michael J. Reardon,N. M. Van Mieghem,Jeffrey J. Popma,Neal S. Kleiman,Lars Søndergaard,Mubashir Mumtaz,David H. Adams,G. M. Deeb,Brijeshwar Maini,Hemal Gada,Stanley Chetcuti,Thomas G. Gleason,John Heiser,Ruediger Lange,William Merhi,Jae Oh,Peter Skov Olsen,Nicolo Piazza,M. Williams,Stephan Windecker,Steven J. Yakubov,Eberhard Grube,Raj Makkar,Jonathan S. Lee,John V. Conte,E. Vang,Hang Nguyen,Yanping Chang,Andrew S. Mugglin,Patrick W. Serruys,Arie-Pieter Kappetein +30 more
TL;DR: TAVR was a noninferior alternative to surgery in patients with severe aortic stenosis at intermediate surgical risk, with a different pattern of adverse events associated with each procedure.
Journal ArticleDOI
Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery.
Jeffrey J. Popma,David H. Adams,Michael J. Reardon,Steven J. Yakubov,Neal S. Kleiman,David Heimansohn,James B. Hermiller,G. Chad Hughes,J. Kevin Harrison,Joseph S. Coselli,Jose G Diez,Ali Kafi,Theodore Schreiber,Thomas G. Gleason,John V. Conte,Maurice Buchbinder,G. Michael Deeb,Blase A. Carabello,Patrick W. Serruys,Sharla Chenoweth,Jae K. Oh +20 more
TL;DR: TAVR with a self-expanding bioprosthesis was safe and effective in patients with symptomatic severe aortic stenosis at prohibitive risk for surgical valve replacement.
Journal ArticleDOI
2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement
Michael J. Reardon,David H. Adams,Neal S. Kleiman,Steven J. Yakubov,Joseph S. Coselli,G. Michael Deeb,Thomas G. Gleason,Joon S. Lee,James B. Hermiller,Stan Chetcuti,John Heiser,William Merhi,George L. Zorn,Peter Tadros,Newell Robinson,George Petrossian,G. Chad Hughes,J. Kevin Harrison,Brijeshwar Maini,Mubashir Mumtaz,John V. Conte,Jon R. Resar,Vicken Aharonian,Thomas A. Pfeffer,Jae K. Oh,Hongyan Qiao,Jeffrey J. Popma +26 more
TL;DR: In patients with severe aortic stenosis who are at increased surgical risk, the higher rate of survival with a self-expanding TAVR compared with surgery was sustained at 2 years.